EnhancerAtlas 2.0: an updated resource with typical enhancer annotation in 600 tissue/cell types across nine species
EnhancerAtlas 2.0
TagContent
EnhancerAtlas ID
HS110-02996 
Organism
Homo sapiens 
Tissue/cell
KATO3 
Coordinate
chr20:30197970-30200000 
TF binding sites/motifs
Number: 7             
TFJASPAR IDCoordinateMotif SequenceStrand-Log10(p-value)
HES2MA0616.2chr20:30199311-30199321GGCACGTGCC+6.02
HES2MA0616.2chr20:30199311-30199321GGCACGTGCC-6.02
Nr2f6(var.2)MA0728.1chr20:30199388-30199403TGACCTTCTGACCTC-7.52
RARAMA0729.1chr20:30199385-30199403TCTTGACCTTCTGACCTC-7.51
STAT1MA0137.3chr20:30198568-30198579TTTCCAGGAAA+6.62
Stat4MA0518.1chr20:30198568-30198582TTTCCAGGAAAGGG+7.64
ZNF263MA0528.1chr20:30198607-30198628GGAGGAGCACAGGGAGGGGCG+6.05
Number of super-enhancer constituents: 27             
IDCoordinateTissue/cell
SE_02970chr20:30198290-30198767Bladder
SE_02970chr20:30199332-30199745Bladder
SE_23092chr20:30198143-30200173Colon_Crypt_1
SE_23905chr20:30198313-30199277Colon_Crypt_2
SE_23905chr20:30199346-30199605Colon_Crypt_2
SE_24856chr20:30198129-30199158Colon_Crypt_3
SE_24856chr20:30199310-30200138Colon_Crypt_3
SE_27857chr20:30191494-30200969Fetal_Intestine
SE_28873chr20:30191441-30200905Fetal_Intestine_Large
SE_31829chr20:30191527-30198255Gastric
SE_31829chr20:30198270-30199761Gastric
SE_33920chr20:30196505-30198178HCC1954
SE_33920chr20:30198212-30200846HCC1954
SE_34238chr20:30189210-30201146HCT-116
SE_34664chr20:30188903-30201189HeLa
SE_38269chr20:30190026-30200015HUVEC
SE_41187chr20:30198022-30199309Left_Ventricle
SE_42444chr20:30198233-30199786Lung
SE_47160chr20:30189148-30200294Panc1
SE_48882chr20:30198252-30199227Right_Atrium
SE_50279chr20:30191498-30200037Sigmoid_Colon
SE_52484chr20:30191540-30200981Small_Intestine
SE_54437chr20:30197753-30199818Spleen
SE_55719chr20:30198018-30199221u87
SE_57184chr20:30198195-30200129VACO_400
SE_57391chr20:30198295-30199172VACO_503
SE_67492chr20:30198018-30199221u87
Diseases: AD,Huntington,Obesity,Parkinson,Prostate cancer,Schizophrenia and Sleep disorder
Number of disease enhancers: 2             
ChromosomeStartEnd
chr203019829030199039
chr203019937130199990
Enhancer Sequence
CACCATGTTT GCCAGGCTGC TCTCGAACTC CTGACCTCAG GTGATCTACC CTCCTCAGCC 60
TCCCAAAGTG CATGAGGCCA CCGTGCCCGG CTCTTTTTTT TTTTTTTTTT TTTTTTTTGA 120
GACAGAGTCT CGCTCTGTCG CCCAGGCTGG AGTGCAGTGG CGTGATCTTG GCTCATTGCA 180
ACCTCCGCCT CCCGGGTTCA AGCAATTCTC ATGCCTCAGC CTCCTGAGTA GCTGAGATTA 240
CAGACGCGCA CCACCACATC TGGCTAATTT TTATATATTT AGTAGAGACG GGGTTTCACC 300
ATGTTGCCCA GGCTGGCCTC GAACTCCTGA CCTCAGGTGA TCAGCCCTCC TCAACCTCCC 360
AAAGTGCTGG GATTACAGGC GTGAGCCACC ACACCCGACC CATGCCAGTC ACTCTTATTG 420
AGCACCAGGA ACTGCCAGCC AGAGAGAGCT CCCTGCTGCC CAGTGTCACA CACAGCAGGG 480
CTTCCTGGTG GCAGGCAGGT CTCACATCCT AGCATGGCTG CCGGAAAGAA AGGAGGTGAG 540
TCACAGGGCC AGGCCAGGAG CTGGGCGAGG CTGGGGCCAG GGTCCAGGCA GGCGCCACTT 600
TCCAGGAAAG GGAAGGGAAG AGGAAACCAG AAGGCCAGGA GGAGCACAGG GAGGGGCGAG 660
GGTGCCCTTA TCTCCCTGGA CCTGCCCTGG CTGGTGCTGC TTCCTGCTGC AACTCTTGCA 720
AAACCTCGTT CCCAACGCTG TCCTCAAGCA GGGTGCCCCA GGCCAGTACA GGGTTGCATC 780
AAGGCCTTGT GCAAGGGGGG TTAAAGGGAG GACAGTGGCT GGGAGCAAAG GCAGGGCAAG 840
AGGCAAGGCA AATGCGGGTT CTAGGCCCAG TGCCACTTCT GGTTGGGCAC CTGCTTCACC 900
TCCTGGGCTC TTAGGATCCC CAGCATTTTT TTTTTTTTTT TTGAGACGGA GTCTCACTCT 960
GTTGCCAACC TCTGCCTCCT GGGTTCAAGC AATTCTCCTG CCTCAGCCCC TCCAGTAGCT 1020
GAGTCTACCG GTGTGCACCA CGACGCCCAG CAATTTTTGT ATTTTTAGTA GAGACAGGGT 1080
TTCTACATGT TGGCCAGGTT GGTCTCGAAC TACTGACCTC AGGTGATCCA CCTGCCTTGG 1140
CCTCCCAAAT TGTTGGGATT ACAGGTGTGA GCCACTGCAC CCTGCCATCC CCAGCATTTT 1200
TTTTTTTTTT TTTTTTTTGA GACAGAGTCT CCCTCTCTTG CTAGCCTGGA GTGCAGTGGC 1260
AGGAGCTCAG CTCACTGCAA CCTGTGTCTC CCAGGTTCAA GTGATTCTCC TGCCTCACCC 1320
TCCCAAGTAG CTGGGGTTAT AGGCACGTGC CACCACGCCC AGCTAATTTT TGTGTTTTTA 1380
GTAGAGACGG GGTTTCACCG TGTTGGCCAG GTTGGTCTTG ACCTTCTGAC CTCGTGGTCT 1440
GCCCGCCTTG GCCTCCCAAA GTGCTGGGAT TACAGGTGTG AGCCACCATG TCGCCCAGCC 1500
TCATTCCCAG CTTTTAAATG GGTGTTATAC TCACCGTTTT GAGGTTTCAG TGATATCATC 1560
CCAAACCTTT GCACTCCTCA AGCCTCAGGC TAGGCCATTG TACTTCTACC TGTGAAACTA 1620
GCCCCAACTG GTTCTTTCAA CAAATAGTTT ATAAAGCTTC TACAATATAC TAGGAACCGG 1680
GCCCCAGGAG TTAACAATTC AGATACAAAT TCTTGCAGTC TTGGAACTTA CATTCTTAGT 1740
GGGAGACACG CAGTAGATAA ATATGCAGAT GTGTAATCAG AGGTGCATTT ACCTGGAAAT 1800
TACTTAAGCT TAAACTTCAA GCCTCCTCAC ATGGAAAGAG TATCAGCCAT GTGTTAGCAT 1860
GATTTCTGTG TGTTTTGCAA GATTTGCAAA ATGTTGTATT CTTTTCCTTA GAGGCTGCAC 1920
AAACCTAGAT CCTCTTCTTT ATATATAGAC GAGACCGAGC AGGGCCCAAG CTTGAAGGCA 1980
TAGCTGCAGA AGACAAAGAA TCGTGTCTGT GGGTGCTGTT CGTTGCTTGG 2030